Spot by NetApp Delivers Cloud Desktop-as-a-Service Solution for Service Providers, Enterprises and Today’s Distributed Workforce
17.5.2022 15:00:00 EEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the general availability of Spot PC, the managed cloud Desktop-as-a-Service (DaaS) solution — with security, automation, observability and optimization designed for the public cloud and for the needs of today’s remote and distributed working environments.
Available today, Spot PC provides Managed Service Providers (MSPs) and their customers with a cloud desktop solution optimized for security, privacy and infrastructure efficiency, with predictable pricing to reduce overall support burdens and allow existing staff to deliver and support many more desktops, increasing profitability.
With the rapid acceleration of hybrid work environments, organizations have been compelled to evolve their IT infrastructure to support remote work environments, building distributed teams, and enabling hybrid offices while navigating supply chain issues and cyber security threats.
But the most common solutions available to deliver remote desktops, based on traditional virtual desktop infrastructure (VDI) were never designed for the public cloud and therefore require significant effort for administration, management and troubleshooting. As a result, today’s remote desktop offerings come with significant operations burdens, can be time consuming and complex to set up, migrate to, and manage, and are expensive to deploy and operate.
“Service providers and enterprises today require the right tools and solutions that are built for the cloud for optimal efficiency of their resources,” said Anthony Lye, Executive Vice President of Public Cloud Services at NetApp. “With Spot PC, we’re equipping MSPs and enterprises to bring differentiated, profitable cloud desktop solutions to market to meet growing demand from their customers and enabling them to deliver flexible, secure and fit-for-purpose remote work experiences to a variety of users across multiple locations and regions.”
Spot PC delivers a comprehensive as-a-service solution to these challenges, enabling MSPs and enterprises to provide secure, reliable, and fully optimized cloud desktops to support a broad range of needs.
Spot PC provides MSPs and enterprises with the ability to:
- Deliver cloud desktops with speed, flexibility and agility across multiple locations and regions to support a wide range of tasks for knowledge and technical computing users
- Ensure that cloud desktop environments meet security, availability and performance requirements without overburdening IT staff
- Provide predictable cost structure using patent-pending AI and machine learning automated optimization
“We are really excited for Spot PC and the benefits and automation it will provide us and our clients,” said Derek Anderson, President at Biztek Solutions. “We see Spot PC as the go to solution for secure, cloud hosted desktops that will enable businesses to adopt remote and hybrid work environments that easily scale with their business.”
“Working with NetApp has meant that Cloud PC as a Service has become an exciting prospect for our clients to enjoy Spot PC, combined with complete support for the virtual desktop and the office suite that our clients use,” said Peter Beglan, CEO at Cloud PC Ltd & HyCloud Ltd. “We are so confident that this combined virtual desktop solution will be eagerly received in the UK that we have already made plans to start offering Cloud PC as a Service within the European marketplace.”
Spot PC is available today, direct from NetApp for enterprises and service providers with a fixed pricing structure per user per month.
Additional Resources:
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005461/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom